EPOR and breast cancer: A study reported significant positive correlation between erythropoietin receptor (EPOR) and erb‐b2 receptor tyrosine kinase 2 (ERBB2) levels in breast cancer, both of which are targeted by miR‐125b and behave as ceRNA (Ferracin et al., 2013).